CML-CP: Elevated creatine kinase levels during first-line TKI treatment associated with improved survival

Key clinical point: Creatine kinase (CK) elevation was associated with superior survival in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving first-line tyrosine kinase inhibitor (TKI) therapies.

Major finding: Overall, 71.7% patients had CK elevation after TKI initiation. Patients with vs. without elevated CK levels had improved overall survival (adjusted hazard ratio [aHR] 0.31; P < .001) and event-free survival (aHR 0.51; P = .003).

Study details: This retrospective study included 283 patients with newly diagnosed CML-CP treated with first-line TKI therapies.

Disclosures: No source of funding was identified. A Bankar reported consulting for Novartis and Celgene. JH Lipton reported consulting for and research funding from Novartis, BMS, Pfizer, and Takeda.

Source: Bankar A et al. Leuk Lymphoma. 2021 Sep 8.doi: 10.1080/10428194.2021.1971219.

Key clinical point: Creatine kinase (CK) elevation was associated with superior survival in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving first-line tyrosine kinase inhibitor (TKI) therapies.

Major finding: Overall, 71.7% patients had CK elevation after TKI initiation. Patients with vs. without elevated CK levels had improved overall survival (adjusted hazard ratio [aHR] 0.31; P < .001) and event-free survival (aHR 0.51; P = .003).

Study details: This retrospective study included 283 patients with newly diagnosed CML-CP treated with first-line TKI therapies.

Disclosures: No source of funding was identified. A Bankar reported consulting for Novartis and Celgene. JH Lipton reported consulting for and research funding from Novartis, BMS, Pfizer, and Takeda.

Source: Bankar A et al. Leuk Lymphoma. 2021 Sep 8.doi: 10.1080/10428194.2021.1971219.

Key clinical point: Creatine kinase (CK) elevation was associated with superior survival in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) receiving first-line tyrosine kinase inhibitor (TKI) therapies.

Major finding: Overall, 71.7% patients had CK elevation after TKI initiation. Patients with vs. without elevated CK levels had improved overall survival (adjusted hazard ratio [aHR] 0.31; P < .001) and event-free survival (aHR 0.51; P = .003).

Study details: This retrospective study included 283 patients with newly diagnosed CML-CP treated with first-line TKI therapies.

Disclosures: No source of funding was identified. A Bankar reported consulting for Novartis and Celgene. JH Lipton reported consulting for and research funding from Novartis, BMS, Pfizer, and Takeda.

Source: Bankar A et al. Leuk Lymphoma. 2021 Sep 8.doi: 10.1080/10428194.2021.1971219.